Results 61 to 70 of about 11,226 (207)

Daratumumab for the treatment of refractory ANCA-associated vasculitis [PDF]

, 2023
Objective Treatment-refractory antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) is a life-threatening condition without evidence-based treatment options.
Schreiber, Adrian, Mei, Henrik, Kai-Uwe Eckardt, Kerstin Amann, Schreiber, A., Lennard Ostendorf, Amann, K., Dimitrios Laurin Wagner, Henrik Mei, Eckardt, Kai-Uwe, Evelyn Seelow, Adrian Schreiber, Wagner, Dimitrios Laurin, Enghard, Philipp, Marie Burns, Philipp Enghard, Burns, M., Enghard, P., Ostendorf, L., Seelow, E., Wagner, D.L., Burns, Marie, Eckardt, K.U., Ostendorf, Lennard, Seelow, Evelyn, Amann, Kerstin, Mei, H.   +26 more
core   +1 more source

Best Practice for the Administration of Daratumumab in Multiple Myeloma: Australian Myeloma Nurse Expert Opinion

Asia-Pacific Journal of Oncology Nursing, 2018
Patients with multiple myeloma (MM) are typically of an advanced age and may have significant co-existing medical conditions. They have often had multiple lines of therapy and as such experience disease-related effects alongside associated treatment ...
Tracy King, Jacqueline Jagger, Jodie Wood, Carmel Woodrow, Alicia Snowden, Sally Haines, Christina Crosbie, Kristen Houdyk   +7 more
doaj   +1 more source

Nanobodies as next‐generation targeting platforms: From discovery technologies to translational biomedicine

VIEW, EarlyView.
Nanobodies, derived from the variable domains of camelid heavy‐chain‐only antibodies, have emerged as transformative biomedical tools due to their nanoscale size, exceptional stability, and unique capacity to recognize cryptic epitopes. This review provides a comprehensive overview of the field, outlining the structural and biochemical features of ...
Zhenrui Ye, Xianyang Li, Meixiao Zhan
wiley   +1 more source

Daratumumab plus lenalidomide and dexamethasone versus lenalidomide and dexamethasone in relapsed or refractory multiple myeloma: Updated analysis of POLLUX

, 2018
In the POLLUX study, daratumumab plus lenalidomide/dexamethasone significantly reduced risk of progression/death versus lenalidomide/ dexamethasone alone in relapsed/refractory multiple myeloma. We provide one additional year of follow up and include the
Cochrane, T, Leiba, M, Joy Ho, P, San-Miguel, J, White, D, Kaufman, JL, Morton, J, Takezako, N, Belch, A, Cook, G, Dimopoulos, MA, Benboubker, L, Moreau, P, Kim, K, et al.   +14 more
core   +1 more source

Daratumumab for autoimmune diseases: a systematic review

, 2023
Objective Refractory autoimmune diseases remain a significant challenge in clinical practice and new therapeutic options are needed. This systematic review evaluates the existing reported data on the CD38-targeting antibody daratumumab as a new ...
Martin Krusche, Lennard Ostendorf, Nikolas Ruffer, Ina Kötter, Marie-Therese Holzer, Tobias B. Huber   +5 more
core   +1 more source

Serological responses against seasonal influenza viruses in patients with multiple myeloma treated or untreated with daratumumab after two doses of tetravalent vaccine

International Journal of Infectious Diseases
Objectives: Daratumumab-treated myeloma patients may face increased seasonal influenza risk due to weakened postvaccination immune responses, especially with daratumumab treatment.
Simon B. Gressens, Vincent Enouf, Antoine Créon, Giovanna Melica, Francois Lemonnier, Jehan Dupuis, Taoufik El Gnaoui, Mohammad Hammoud, Karim Belhadj, Corinne Haioun, Anne Le Bouter, Sebastien Gallien, Fabien Le Bras, Slim Fourati   +13 more
doaj   +1 more source

Controversy in the Use of CD38 Antibody for Treatment of Myeloma: Is High CD38 Expression Good or Bad?

Cells, 2020
During a time span of just a few years, the CD38 antibody, daratumumab, has been established as one of the most important new drugs for the treatment of multiple myeloma, both in the relapsed/refractory setting and, more recently, as a first-line ...
Torben Plesner, Niels W. C. J. van de Donk, Paul G. Richardson   +2 more
doaj   +1 more source

Efficacy and Tolerability of Weekly Bortezomib, Lenalidomide, and Dexamethasone Protocols in Transplant‐Ineligible Newly Diagnosed Myeloma: An Australian Real‐World, Multicenter Study

Asia-Pacific Journal of Clinical Oncology, EarlyView.
RVD with weekly bortezomib dosing in real‐world newly diagnosed transplant‐ineligible myeloma shows comparable efficacy and reduced toxicity compared to twice‐weekly trial protocols. ABSTRACT Background Lenalidomide, bortezomib, and dexamethasone (RVD) remains a standard of care regimen for newly diagnosed multiple myeloma in centers without access to ...
Samantha Kurniawan, Angela Hwang, Nicole Wong Doo, Tracy King, Christian Bryant, Jennifer Zhang, Kristina Whelan, Parisa Fani‐Molky, Giselle Kidson‐Gerber, Annmarie Bosco, Nada Hamad, Gurdeep Parmar, Fiona Kwok, Sam Lai, Silvia Ling, P. Joy Ho, Georgia McCaughan, Adam Bryant   +17 more
wiley   +1 more source

Daratumumab: A Review in Newly Diagnosed Systemic Light Chain Amyloidosis

, 2022
DeclarationsFunding The preparation of this review was not supported by any external funding.Authorship and Conflict of interest Hannah Blair is a salaried employee of Adis International Ltd/Springer Nature, and declares no relevant conflicts of interest.
Hannah A. Blair (6846307)
core   +1 more source

Pulmonary tuberculosis infection and CMV reactivation following daratumumab treatment in a patient with relapsed plasmablastic lymphoma

Blood Science, 2022
Plasmablastic lymphoma (PBL) is an aggressive lymphoma with limited treatment strategies. Tuberculosis (TB) infection poses a high risk for patients with hematologic malignancies, especially those treated with immune agents but were never reported post ...
Wenyue Cao, Yuling Wan, Xingcheng Yang, Wei Huang, Jia Wei   +4 more
doaj   +1 more source